Cypress Bioscience (CYPB) Reports Q1 Loss of $0.24
More News related to CYPB
- Cypress Bioscience Announces Third Quarter 2009 Financial Results
- Oppenheimer Upgrades Cypress Bioscience (CYPB) to Outperform
- Cypress Bioscience, Inc. to Present at Oppenheimer 20th Annual Healthcare Conference
- Forest Lab (FRX) and Cypress Bio (CYPB) Announce Savella Phase III Results
- Forest Laboratories and Cypress Bioscience Announce Study Shows Patients Treated with Savella Experience Improvements in Pain and Physical Function
More News related to Earnings
- Avondale Securities Upgrades J.B. Hunt Transport (JBHT) to Outperform
- BMO Capital Upgrades Suncor Energy (SU) to Outperform
- MF Global Upgrades ArcelorMittal (MT) to Buy
- Ardour Upgrades Exide Tech. (XIDE) to Buy, $9 Target
- Citi Upgrades Mirant (MIR) to Hold
Cypress Bioscience, Inc. (NASDAQ: CYPB) reports Q1 loss of $0.24, versus the analyst estimate of $0.12 and compared to a loss of $0.08 in the same period last year. Revenue for the quarter was $7.9 million, versus the consensus of $14.61 million.
Related Categories
EarningsStocks Mentioned
-0.70Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
